Bio-Techne (TECH) Other Non-Current Assets (2010 - 2026)
Bio-Techne (TECH) recorded quarterly Other Non-Current Assets of $264.4 million in Q1 2026, down 1.02% quarter-over-quarter from $267.1 million in Q4 2025, and down 1.72% on a YoY basis from $269.0 million in Q1 2025.
Bio-Techne (TECH) Other Non-Current Assets (2010 - 2026) Analysis & Trends
Bio-Techne's Other Non-Current Assets history runs 17 years deep, the most recent figure standing at $264.4 million for Q1 2026.
- In Q1 2026, Other Non-Current Assets fell 1.72% year-over-year to $264.4 million; the TTM figure through Mar 2026 stood at $264.4 million (down 1.72% YoY), while the FY2025 annual figure was $12.3 million, down 95.33% from the prior year.
- Other Non-Current Assets was $264.4 million for Q1 2026 at Bio-Techne, down from $267.1 million in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $285.3 million in Q2 2023 to a low of $1.0 million in Q4 2024.
- Historically, Other Non-Current Assets has averaged $159.6 million across 5 years, with a median of $264.3 million in 2024.
- The sharpest annual moves came in 2024 and 2025: Other Non-Current Assets sank 96.64% in 2024, then jumped 25409.46% in 2025.
- A 5-year view of Other Non-Current Assets shows it stood at $53.2 million in 2022, then tumbled by 49.91% to $26.6 million in 2023, then plunged by 96.07% to $1.0 million in 2024, then surged by 25409.46% to $267.1 million in 2025, then slipped by 1.02% to $264.4 million in 2026.
- The last three Other Non-Current Assets figures came in at $264.4 million (Q1 2026), $267.1 million (Q4 2025), and $276.6 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 289.41 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 12.40 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 60,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.26 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Bio-Techne | 9.04 Bn | 8.83 Bn | 208.29 Mn | 264.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 264.37 Mn |
| Dec 31, 2025 | 267.08 Mn |
| Sep 30, 2025 | 276.56 Mn |
| Jun 30, 2025 | 12.33 Mn |
| Mar 31, 2025 | 268.99 Mn |
| Dec 31, 2024 | 1.05 Mn |
| Sep 30, 2024 | 9.46 Mn |
| Jun 30, 2024 | 264.27 Mn |
| Mar 31, 2024 | 272.14 Mn |
| Dec 31, 2023 | 26.65 Mn |
| Sep 30, 2023 | 281.58 Mn |
| Jun 30, 2023 | 285.30 Mn |
| Mar 31, 2023 | 283.35 Mn |
| Dec 31, 2022 | 53.19 Mn |
| Sep 30, 2022 | 53.90 Mn |
| Jun 30, 2022 | 46.83 Mn |
| Mar 31, 2022 | 45.98 Mn |
| Dec 31, 2021 | 37.11 Mn |
| Sep 30, 2021 | 11.59 Mn |
| Jun 30, 2021 | 11.58 Mn |